Devices for aerosol delivery to treat sinusitis.

Compared to research into aerosolized delivery of drugs to treat lung disease, research into nasal delivery of aerosolized drugs to treat sinusitis has been significantly neglected. This is despite the fact that more individuals suffer from sinusitis in the United States than suffer from asthma, and its consequences lead to considerable amounts of discomfort, lost work days, and money spent on health care. A number of studies have shown that a high proportion of aerosolized medications delivered by metered dose inhalers (MDIs) and aqueous spray devices deposits in the anterior one-third of the nasal cavity. However, the important targets for treating sinusitis lie beyond this region. These include the middle meatus, the superior and posterior regions of the nasal cavity and the sinuses themselves. This review examines the particle-related and device-related factors that are known to improve intranasal delivery of aerosolized medications to these targets and their efficacy in patients with disease. Based on this review, it is recommended that companies that are interested in improving aerosol delivery to treat sinusitis utilize both in vivo imaging modalities and in vitro models of the nasal cavity and sinuses to assess intranasal aerosol delivery and device performance during the development stage. Once device design has been optimized, it is recommended that device manufacturers and pharmaceutical companies move beyond the current reliance on anecdotal reporting and uncontrolled studies to clinical trials that are randomized and placebo-controlled and that quantify changes both in symptoms and in functional parameters to determine drug efficacy with their device.

[1]  R. Naclerio,et al.  Ragweed allergic rhinitis and the paranasal sinuses. A computed tomographic study. , 1997, Archives of otolaryngology--head & neck surgery.

[2]  S. Newman,et al.  Nasal distribution of budesonide inhaled via a powder inhaler. , 1993, Rhinology.

[3]  S. Clarke,et al.  The nasal distribution of metered does inhalers , 1987, The Journal of Laryngology & Otology.

[4]  G. Karlsson,et al.  A randomized trial of intranasal beclomethasone dipropionate after polypectomy. , 1982, Rhinology.

[5]  H. Takano,et al.  Particle Deposition of Therapeutic Aerosols in the Nose and Paranasal Sinuses after Transnasal Sinus Surgery: A Cast Model Study , 2004, American journal of rhinology.

[6]  R. Mösges,et al.  Topical Treatment of Rhinosinusitis with Fusafungine Nasal Spray , 2002, Arzneimittelforschung.

[7]  H. Takano,et al.  Particle deposition efficiency of therapeutic aerosols in the human maxillary sinus. , 1989, Rhinology.

[8]  R. Goode,et al.  State of the Art Review: Current Status of Topical Nasal Antimicrobial Agents , 2000 .

[9]  Beth L. Laube,et al.  Validity of in Vitro Tests on Aqueous Spray Pumps as Surrogates for Nasal Deposition , 2004, Pharmaceutical Research.

[10]  N. Bateman,et al.  A study of intranasal distribution of azelastine hydrochloride aqueous nasal spray with different spray techniques. , 2002, Clinical otolaryngology and allied sciences.

[11]  M. Prince,et al.  Analysis of the intranasal distribution of ointment. , 1997, The Journal of otolaryngology.

[12]  M. Knowles,et al.  Mucus clearance and lung function in cystic fibrosis with hypertonic saline. , 2006, The New England journal of medicine.

[13]  S. Clarke,et al.  Deposition pattern of nasal sprays in man. , 1988, Rhinology.

[14]  B. Laube,et al.  The Effect of Formulation Variables and Breathing Patterns on the Site of Nasal Deposition in an Anatomically Correct Model , 2005, Pharmaceutical Research.

[15]  Julia S. Kimbell,et al.  COMPUTATIONAL FLUID DYNAMICS SIMULATIONS OF INSPIRATORY AIRFLOW IN THE HUMAN NOSE AND NASOPHARYNX , 1998 .

[16]  P. Keith,et al.  Efficacy and tolerability of fluticasone propionate nasal drops 400 μg once daily compared with placebo for the treatment of bilateral polyposis in adults , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[17]  Timothy A. Miller,et al.  Comparison of Topical Medication Delivery Systems after Sinus Surgery , 2004, The Laryngoscope.

[18]  M. M. Mozell,et al.  Numerical simulation of airflow in the human nasal cavity. , 1995, Journal of biomechanical engineering.

[19]  J. Hardy,et al.  Intranasal drug delivery by spray and drops , 1985, The Journal of pharmacy and pharmacology.

[20]  M. Durand,et al.  Preliminary study of the deposition of aerosol in the maxillary sinuses using a plastinated model. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[21]  J. Homer,et al.  A quantitative analysis of the intranasal delivery of topical nasal drugs to the middle meatus: spray versus drop administration , 2002, The Journal of Laryngology & Otology.

[22]  S. Lethagen,et al.  Effect of viscosity on particle size, deposition, and clearance of nasal delivery systems containing desmopressin. , 1988, Journal of pharmaceutical sciences.

[23]  B. Laube,et al.  Comparison of Nasal Deposition and Clearance of Aerosol Generated by a Nebulizer and an Aqueous Spray Pump , 1999, Pharmaceutical Research.

[24]  R. Hilsinger,et al.  Radiographic Comparison of Three Methods for Nasal Saline Irrigation , 2002, The Laryngoscope.

[25]  Ravi P. Subramaniam Regina B. Richa.  COMPUTATIONAL FLUID DYNAMICS SIMULATIONS OF INSPIRATORY AIRFLOW IN THE HUMAN NOSE AND NASOPHARYNX , 1998 .

[26]  M. Desrosiers,et al.  Treatment of Chronic Rhinosinusitis Refractory to Other Treatments with Topical Antibiotic Therapy Delivered by Means of a Large-Particle Nebulizer: Results of a Controlled Trial , 2001, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[27]  D. Shoseyov,et al.  Treatment with hypertonic saline versus normal saline nasal wash of pediatric chronic sinusitis. , 1998, The Journal of allergy and clinical immunology.